For citations:
Solovev M.V., Solovevа M.V., Mendeleeva L.P., Pospelova T.I., Skvortsova N.V., Voloshin S.V., Garifullin A.D., Chuprakova A.S., Mitina T.A., Usankin I.S., Vasileva I.V., Medvedeva N.V., Ryabchikova V.V., Kiseleva M.Ya., Dudina G.A., Gammershmidt Yu.S., Kuznetsova O.S., Dolgushina Yu.V., Kuchma G.B., Tsyganok T.N., Misyurina E.N., Zhelnova E.I., Kopylova A.V., Zakharova M.N., Korobkin A.V., Tumyan G.S., Semenova A.A., Kirillova E.G., Volodicheva E.M., Bakhtina V.I., Olkhovik T.I., Solovkova N.R., Demchenkova M.V., Ochirova O.E., Panteleeva O.L., Abramova V.S. Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia. Oncohematology. 2024;19(4):115-123. (In Russ.) https://doi.org/10.17650/1818-8346-2024-19-4-115-123
Email this article 